Skip to content
Blerp – Lifestyle
Author:
Vroom, Inc.
Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP
August 20, 2026
Vroom Announces Second Quarter 2026 Results
August 4, 2026
Biodexa Initiates Support Activities for FAP Patients and Treatment Centers in France
July 29, 2026
Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress
June 29, 2026
Vroom Announces First Quarter 2026 Results $98.4 million stockholders’ equity as of March 31, 2026
May 15, 2026
Vroom Announces First Quarter 2026 Results $98.4 million stockholders’ equity as of March 31, 2026
May 15, 2026